Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERES: Trastuzumab plus chemo-immunotherapy for HER2-positive esophageal squamous cell carcinoma
2024-516318-40-02Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Rigshospitalet. Primary endpoint: Primary response endpoint. Started Nov 2024; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2024-516318-40-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516318-40-02.